APP and Alzheimer disease: In agreement with these data, a recent study demonstrates that CXCL12 mediates the neuroprotective and anti-amyloidogenic actions of human painless NGF (hNGFp) treatment in 5xFAD mice, transgenic mice that co-overexpress five familial AD mutant forms of human APP and presenilin 1 (Capsoni et al., 2017).